Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 2
Submit an article Journal homepage
1,623
Views
13
CrossRef citations to date
0
Altmetric
Research Paper

Changing epidemiological characteristics of Hepatitis A and warning of Anti-HAV immunity in Beijing, China: a comparison of prevalence from 1990 to 2017

Huai WangDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
,
Pei GaoDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
,
Weixin ChenDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
,
Shuang BaiDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
,
Min LvDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
,
Wenyan JiDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
,
Xinghuo PangDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaView further author information
&
Jiang WuDepartment of immunization, Beijing Center for Disease Prevention and Control, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 420-425 | Received 10 Jul 2018, Accepted 22 Sep 2018, Published online: 12 Oct 2018

References

  • Cui F, Hadler SC, Zheng H, Wang F, Zhenhua W, Yuansheng H, Gong X, Chen Y, Liang X. Hepatitis A surveillance and vaccine use in China from 1990 through 2007. J Epidemiol. 2009;19:189–195. PMID: 19561383; doi:10.2188/jea.JE20080087.
  • Rein DB, Fiore AE, Bell BP. What’s next for the hepatitis A vaccine. Lancet. 2006;367:546–548. PMID: 16488780. doi:10.1016/S0140-6736(06)68196-8.
  • Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, Shouval D, Bonanni P, Connor B, Cooksley G, et al. International Consensus Group on Hepatitis A virus immunity. Hepatitis A booster vaccination: is there a need?. Lancet. 2003;362:1065–1071. PMID:14522539; doi:10.1016/S0140-6736(03)14418-2.
  • Webster G, Barnes E, Dusheiko G, Franklin I. Protecting travelers from hepatitis A. BMJ. 2001;322:1194–1195. PMID: 11358758.
  • Xu ZY, Wang XY, Zhao SJ. The efficacy and strategy of live attenuated hepatitis A vaccine. Zhonghua Liu Xing Bing Xue Za Zhi. 23;2002:394–396.
  • Wang XJ, Zhang RZ, Hu YS. Analysis on epidemic status of viral hepatitis in China: the report from Chinese Center for Disease Control and Prevention. Dis Surveill. 19;2004:209.
  • Zhang ZL, Zhu XJ, Shan AL, Gao ZG, Zhang Y, Ding YX, Liu H, Wu WS, Liu Y, He HY, et al. Effectiveness of 10-year vaccination (2001-2010) on hepatitis A in Tianjin, China. Human Vaccines and Immunotherapeutics. 2014;10(4):1008–1012. PMID: 24503599.
  • Chen Y, Zhang XJ, Zhao YL, Zhang YH, Wang SM, Hao ZY, Zhang ZY, Ma JC, Fang Y, Wang XY. Waning of anti-HAV immunity in Shijiazhuang prefecture, Hebei Province, China: A comparison of seroprevelence between 1992 and 2011. Vaccine. 2014;32:6227–6232. PMID: 25258099; doi:10.1016/j.vaccine.2014.09.022.
  • Division of viral hepatitis, Centre for Disease Prevention and Control. Surveillance of viral hepatitis United States. 2013 http://www.cdc.gov/hepatitis/statisitcs/2013surveillance/pdfs/2013hepsurveillancerpt.pdf.
  • European Centre for Disease Prevention and Control. Annual epidemiological report 2014_food-and waterborne diseases and zoo noses. 2014 http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1210.
  • Wang ZS, Shepard DS, Zhu YC, Cash RA, Zhao RJ, Zhu ZX, Shen FM. Reduction of enteric infectious disease in rural China by providing deep-well tap water. Bull World Health Organ. 1989;67(2):171–180. PMID: 2501042.
  • Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immunememory in healthy adults following vaccination with a two-dose inactiv-ated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol. 2011;83:1885–1891. PMID: 21915861. doi:10.1002/jmv.22200.
  • Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, Chen JQ, Zhou SY, Lin YX, Xu GZ. Long-term clinical obser-vation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine. 2010;28:4798–4801. PMID: 20471440; doi:10.1016/j.vaccine.2010.04.096.
  • Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year anti-body persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccine Immunother. 2012;8:323–327. PMID: 22327499. doi:10.4161/hv.18617.
  • Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, Loutan L. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis Avaccine. J Med Virol. 2010;82:1629–1634. PMID: 20827757; doi:10.1002/jmv.21883.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.